{"nctId":"NCT01121666","briefTitle":"Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment","startDateStruct":{"date":"2010-06"},"conditions":["Infertility"],"count":460,"armGroups":[{"label":"Gonal-f® (Follitropin alfa)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Follitropin alfa"]},{"label":"AFOLIA-150 (Follitropin alfa)","type":"EXPERIMENTAL","interventionNames":["Drug: Follitropin alfa"]}],"interventions":[{"name":"Follitropin alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age between 20 and 38 years with regular menstrual cycles of 25-35 days\n* First or second cycle in the present series of ART\n* BMI ≥ 18 ≤ 30 kg/m2\n* Basal FSH \\< 10 IU/L (cycle day 2-5)\n* E2 levels \\< 50pg/mL (\\< 0.18 nmol/L) at the day of FSH administration\n* Antral follicle count (AFC) ≥ 10 to ≤ 25 follicles (sum of both ovaries)\n* Infertility due to any of the following factors: tubal factor, mild endometriosis (ASRM stage 1-2), male factor, unexplained infertility\n* Presence of both ovaries and normal uterine cavity (confirmed by transvaginal ultrasound within 6 months before randomisation)\n* Willingness to participate in the study and to comply with the study protocol\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of pregnancy\n* History of ≥2 succeeding ART cycles (IVF and/or ICSI) before the study cycle without clinical pregnancy\n* Presence of clinically significant systemic disease\n* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease\n* Presence of uncontrolled endocrine disorder\n* Previous history or presence of severe ovarian hyperstimulation syndrome\n* Presence of polycystic ovaries (PCO)\n* Presence of severe endometriosis (ASRM stage 3 or stage 4) and hydrosalpinx\n* Neoplasia, including tumors of the hypothalamus and pituitary gland\n* Abnormal bleeding of undetermined origin\n* History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes retrieved in a previous attempt)\n* Male infertility without mobile spermatozoa in the ejaculate, that need testicular of epididymal sperm retrieval (MESA/TESE/TESA)\n* Endocrine abnormality such as TSH or prolactin level elevations outside the reference range if clinically relevant at screening\n* Any hormonal treatment within 1 month before the start of the FSH treatment (with the exception of levothyroxin)\n* History of drug, nicotine or alcohol abuse within the last 12 months (\\> 10 cigarettes/day)\n* Administration of other investigational products within the last month\n* Clinically abnormal findings at Visit 1\n* Planned PGS/PGD/PBB or assisted hatching\n* Concomitant participation in an other study protocol\n* History of extrauterine pregnancy in the previous 3 months\n* Known allergy or hypersensitivity to progesterone or to any of the excipients (including peanut oil) of the additional study medication (GnRH agonist, vitrelle®, and Utrogestan®)\n* Presence or history of thrombophlebitis or thromboembolic disorders\n* Presence or history of cerebral haemorrhage\n* Presence or history of porphyria","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"38 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Oocytes Retrieved (Per Protocol Population)","description":"As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.\n\nThe equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"5.11"},{"groupId":"OG001","value":"10.6","spread":"6.06"}]}]}]},{"type":"SECONDARY","title":"Number and Size of Follicles ≥ 12 mm at Day 8 of Stimulation","description":"The number and size of follicles 12 mm or over in diameter at day 8 of stimulation were evaluated as secondary end-point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"4.73"},{"groupId":"OG001","value":"11.1","spread":"4.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"3.81"},{"groupId":"OG001","value":"7.7","spread":"3.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"3.29"},{"groupId":"OG001","value":"4.5","spread":"2.71"}]}]}]},{"type":"SECONDARY","title":"E2 Concentration at Day 8 and at Day of hCG Administration","description":"The serum concentration of oestradiol was assessed at day 8 and the day of hCG administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8982.3","spread":"6535.3"},{"groupId":"OG001","value":"7704.2","spread":"5345.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3958.9","spread":"3699.4"},{"groupId":"OG001","value":"3234.0","spread":"2428.1"}]}]}]},{"type":"SECONDARY","title":"Total Dose of r-hFSH Administered","description":"Total dose of r-hFSH required was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1555.7","spread":"293.00"},{"groupId":"OG001","value":"1569.2","spread":"259.20"}]}]}]},{"type":"SECONDARY","title":"Quality of Oocytes Retrieved","description":"Number of patients with ovum pick-up","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Fertilisation Rate of Oocytes","description":"Fertilisation rate was assessed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":"24.84"},{"groupId":"OG001","value":"64.0","spread":"24.76"}]}]}]},{"type":"SECONDARY","title":"Embryo Quality: Mean Number of Blastomeres","description":"Main embryo quality parameter \"mean number of blastomeres\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"2.41"},{"groupId":"OG001","value":"6.4","spread":"2.49"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cryopreserved 2PNs, Embryos/Blastocysts","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of r-hFSH Stimulation","description":"Mean duration of stimulation was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"1.91"},{"groupId":"OG001","value":"10.7","spread":"1.72"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Cycle Cancellation","description":"Number of patients with cycle cancellation was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Good Response","description":"Good response was defined as \"patients with an oocyte retrieval of four or more oocytes\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Defined as fetal sac per embryo transferred.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Presence of at least one intrauterine gestational sac.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Ongoing Pregnancy","description":"Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Live Birth Rate","description":"Patients with liveborn children","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Oocytes Retrieved (Intention-to-treat Population)","description":"As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.\n\nThe equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"5.62"},{"groupId":"OG001","value":"10.4","spread":"6.14"}]}]}]},{"type":"SECONDARY","title":"Embryo Quality: Absence of Multinucleation","description":"Main embryo quality parameter \"absence of multinucleation\" observed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Oocytes Retrieved","description":"Number of patients with transferred blastocysts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Oocytes Retrieved","description":"Number of embryos per blastocysts transferred","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.52"},{"groupId":"OG001","value":"1.6","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate (Second Treatment Cycle)","description":"Presence of at least one intrauterine gestational sac.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Ongoing Pregnancy (Second Treatment Cycle)","description":"Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Oocytes Retrieved","description":"The maturity of the cumulus oophorus was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"75.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"14.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Oocytes Retrieved","description":"The nuclear maturity was assessed (Germinal vesicle, Metaphase I, Metaphase II).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":249},"commonTop":["Injection site erythema","Headache","Injection site haematoma","Ovarian hyperstimulation syndrome","Injection site pain"]}}}